Goldman Sachs ups stake in Rossari Biotech, Norges Bank raises holding in IndiaMART

Plutus Wealth Management bought 4,77,637 shares in the company at Rs 669.25 per share.

Goldman Sachs India on July 23 acquired an additional 0.92 percent stake in specialty chemical maker Rossari Biotech via open market transactions.

It bought 4,81,443 equity shares in the company at Rs 692.17, bulk deals data on the National Stock Exchange showed. The deal was at a premium of Rs 267.17 per share over Rossari Biotech's issue price.

Earlier, the global financial advisor had bought 1,95,271 equity shares at an issue price of Rs 425 through the anchor book on June 10.

Rossari Biotech had a stellar debut at Rs 669.25 on the NSE, a 57.5 percent premium over its issue price. The counter closed with 74.51 percent gains at Rs 741.65.

Plutus Wealth Management bought 4,77,637 shares in the company at Rs 669.25 per share.

IndiaMART InterMESH also witnessed three bulk deals on July 23. Norges Bank bought 1,48,920 equity shares in company at Rs 2,350 per share.

However, Amadeus EIII sold 1,62,584 out of the 5,97,014 shares that at owns at Rs 2,381.11 per share. Amadeus IV DPF offloaded 1,96,045 shares out of its holdings of 8,80,817 shares at Rs 2,368.03 per share on the BSE.

Among other deals, Pawan Kumar Yadav bought 2.4 lakh shares in Syncom Healthcare at Rs 1.9 per share. Wheelers Developers acquired 25 lakh shares in Ujaas Energy at Rs 6.25 and promoter SVA Family Welfare Trust sold 51 lakh shares in company at Rs 6.26 per share.

Reliable Data Services sold 2,46,400 shares in Milton Industries at Rs 10.37 per share. Sunny Kantilal Solanki and Ankitkumar Muljibhai Solanki acquired 96,800 and 92,400 shares, respectively, in the company at Rs 10.35 each.

Source - moneycontrolcom

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...

SD Solutions

Search This Blog